Influence of lipoprotein (a) on inflammatory biomarkers in metabolic syndrome

Southern Medical Journal

Volumn 105, Issue 7, 2012, Pages 339-343

  Muñoz Torrero, Juan Francisco Sánchez ^a,b   Rivas, Dolores ^a,b   Alonso, Rodrigo ^a,b   Crespo, Leandro ^a,b   Costo, Alberto ^a,b   Roman, Montaña ^a,b   Martín, Carlos ^a,b   Zamorano, José ^a,b  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

cytokines; inflammation; lipoprotein (a); metabolic syndrome; oxidative stress

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; VASODILATATION;

ADULT; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CYTOKINES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; METABOLIC SYNDROME X; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS;

EID: 84863768381     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31825b5fb2     Document Type: Article

References (21)

1. Gustafson B, Hammarstedt A, Andersson CX, et al. A culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2276-2283.
2. Ergou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423.
3. Koschinsky ML. Lipoprotein(a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein. Curr Atheroscler Rep 2005;7:389-395.
4. Cicek H, Bayil S, Zer Y, et al. Comparison of lipoprotein(a) levels between elderly and middle-aged men with coronary artery disease. Ann N Y Acad Sci 2007;1100:179-184.
5. Orsó E, Ahrens N, Kilali( D, et al. Familial hypercholesterolemia and lipoprotein(a) hyperlipidemia as independent and combined cardiovascular risk factors. Atheroscler Suppl 2009;10:74-78.
6. Onat A, Hergenc G, Ozhan H, et al. Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome. Coron Artery Dis 2008;19:125-131.
7. Guven A, Inanc F, Kilinc M, et al. Plasma homocysteine and lipoprotein (a) levels in Turkish patients with metabolic syndrome. Heart Vessels 2005;20:290-295.
8. Stein JH, Korcarz CE, Hurst RT, et al. American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: A consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by theSociety for Vascular Medicine. J Am Soc Echocardiogr 2008;21:93-111.
9. CorrettiMC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265.
10. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010;17:332-341.
11. Hansson GK, Libby P. The immune response in atherosclerosis: A doubleedged sword. Nat Rev Immunol 2006;6:508-519.
12. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361: 2518-2528.
13. Cushing GL, Gaubatz JW, Nava ML, et al. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989;9:593-603.
14. Kotani K, ShimohiroH,Adachi S, et al. Relationship between lipoprotein(a), metabolic syndrome, and carotid atherosclerosis in older Japanese people. Gerontology 2008;54:361-364.
15. QasimAN,Martin SS,MehtaNN, et al. Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol 2011;150:17-21.
16. Wu HD, Berglund L, Dimayuga C, et al. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J Am Coll Cardiol 2004;43:1828-1833.
17. Edelstein C, Pfaffinger D, Hinman J, et al. Lysine-phosphatidylcholine adducts in Kringle V impart unique immunological and potential proinflammatory properties to human apolipoprotein(a). J Biol Chem 2003; 278:52841-52847.
18. Tsimikas S, Mallat Z, Telmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010;56:946-955.
19. Enkhmaa B, Anuurad E, Zhang W, et al. Lipoprotein(a): Genotypephenotype relationship and impact on atherogenic risk. Metab Syndr Relat Disord 2011;9:411-418.
20. Anuurad E, Rubin J, ChiemA, et al.High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans. J Clin Endocrinol Metab 2008;93:1482-1488.
21. Zago AS, Park JY, Fenty-Stewart N, et al. Effects of aerobic exercise on the blood pressure, oxidative stress and eNOS gene polymorphism in prehypertensive older people. Eur J Appl Physiol 2010;110:825-832.